Tomiyama H, Doba N, Kushiro T, Yamashita M, Yoshida H, Kanmatsuse K, Kajiwara N, Hinohara S
Third Department of Internal Medicine, Teikyo University School of Medicine, Ichihara, Japan.
Hypertens Res. 1997 Jun;20(2):105-11. doi: 10.1291/hypres.20.105.
This study was conducted to investigate the effects of long-term administration of a calcium-channel antagonist (nifedipine) and a beta-blocker (acebutolol) on physical fitness in men with mild hypertension. All subjects underwent symptom-limited treadmill stress testing and routine echocardiographic studies. Twenty-two subjects who had either a causal diastolic blood pressure of more than 105 mmHg or a left ventricular mass index (LVMI) of 125 g/m2 or more during follow-up were assigned to receive medical therapy. The other 31 men who did not meet either criterion were continuously followed-up without medication. Among the 22 treated men, the age-adjusted treadmill time (normalized treadmill time, TMTn) significantly decreased before the initiation of medication, while 31 untreated men showed no change in TMTn throughout the study. The 22 treated subjects were subsequently divided into two groups; 13 were given nifedipine and 9 were given acebutolol. All treated subjects were followed-up for more than 3 years. After treatment, the two groups showed similar reductions in blood pressure and LVMI, but a different outcome for TMTn: TMTn increased from 104 +/- 8% to 115 +/- 16% in subjects given nifedipine (p < 0.05) and decreased from 106 +/- 12% to 99 +/- 10% (p < 0.01) in those given acebutolol. Thus, the physical fitness of subjects who required medication significantly deteriorated without medication; their physical fitness improved after treatment with a calcium-channel antagonist and deteriorated after treatment with a beta-blocker.
本研究旨在探讨长期服用钙通道拮抗剂(硝苯地平)和β受体阻滞剂(醋丁洛尔)对轻度高血压男性体能的影响。所有受试者均接受症状限制的平板运动应激试验和常规超声心动图检查。22名在随访期间舒张压持续高于105 mmHg或左心室质量指数(LVMI)达到或超过125 g/m²的受试者被分配接受药物治疗。另外31名不符合上述任何一项标准的男性则不服药持续随访。在22名接受治疗的男性中,年龄校正后的平板运动时间(标准化平板运动时间,TMTn)在开始用药前显著下降,而31名未治疗的男性在整个研究过程中TMTn没有变化。随后,22名接受治疗的受试者被分为两组;13人服用硝苯地平,9人服用醋丁洛尔。所有接受治疗的受试者均随访超过3年。治疗后,两组血压和LVMI均有相似程度的下降,但TMTn的结果不同:服用硝苯地平的受试者TMTn从104±8%增加到115±16%(p<0.05),而服用醋丁洛尔的受试者TMTn从106±12%下降到99±10%(p<0.01)。因此,需要药物治疗的受试者在未用药时体能显著恶化;在接受钙通道拮抗剂治疗后体能改善,而在接受β受体阻滞剂治疗后体能恶化。